Abstract
Participants at the February 2011 meeting at the U.S. National Institutes of Health on Epstein-Barr virus (EBV) vaccine research recommend that future clinical trials have two goals: prevention of infectious mononucleosis and EBV-associated cancers, facilitated by identification of disease-predictive surrogate markers.
MeSH terms
-
Biomarkers / analysis
-
Congresses as Topic
-
Epstein-Barr Virus Infections / complications
-
Epstein-Barr Virus Infections / diagnosis
-
Epstein-Barr Virus Infections / prevention & control
-
Herpesvirus 4, Human / pathogenicity*
-
Humans
-
Infectious Mononucleosis / diagnosis
-
Infectious Mononucleosis / prevention & control
-
Neoplasms / prevention & control*
-
Neoplasms / virology*
-
Viral Vaccines / therapeutic use*
Substances
-
Biomarkers
-
Viral Vaccines